Summary
Specific estrogen receptor activity (ER) was found in 115 of 175 (66%) tumors of patients treated for primary breast cancer in the period 1974–1981; 60 patients had ER-negative tumors. All patients were under observation for at least 48 months (median 76 months). The 24 patients who received adjuvant chemotherapy as part of their initial treatment, were excluded from the analysis of the disease-free interval (DFI). Groups of patients with ER-positive or ER-negative tumors did not differ significantly in clinical characteristics. Patients with ER-positive tumors had a significantly longer DFI than those with ER-negative tumors only in the first year after initial treatment. After prolonged observation a significant difference in recurrence rates was no longer found. In premenopausal women, the DFI was not different for those with ER-positive compared to those with ER-negative tumors, not even in the first year of observation. However, in postmenopausal women, those with ER-positive tumors had a significantly longer DFI up to 3 years after initial treatment but not thereafter. There was no difference in DFI between the ER-positive and ER-negative groups when the tumor stage was taken into account. It is concluded that the ER status of the primary tumor affects prognosis only on the short term.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Knight WA III, Livingston RB, Gregory EJ, McGuire WL: Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res 37: 4669–4671, 1977
Rich MA, Furmanski P, Brooks SC, and the Breast Cancer Prognostic Study Surgery and Pathology Associates: Prognostic value of estrogen receptor determinations in patients with breast cancer. Cancer Res 38: 4296–4298, 1978
Maynard PV, Blamey RW, Elston CW, Haybittle JC, Griffiths K: Estrogen receptor assay in primary breast cancer and early recurrence of the disease. Cancer Res 38: 4292–4295, 1978
Allegra JC, Lippman ME, Simon R, Thompson EB, Barlock A, Green L, Huff KK, Do HMT, Aitken SL, Warren R: Association between steroid hormone receptor status and disease free interval in breast cancer. Cancer Treat Rep 63: 1271–1277, 1979
Cooke T, George D, Shields R, Maynard P, Griffiths K: Oestrogen receptors and prognosis in early breast cancer. Lancet ii: 995–997, 1979
Kern WH: Morphologic and clinical aspects of estrogen receptors in carcinoma of the breast. Surg Gynecol Obstet 148: 240–242, 1979
Osborne CK, Yochmowitz MG, Knight WA III, McGuire WL: The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46: 2884–2888, 1980
Pichon MF, Pallud C, Brunet M, Milgrom E: Relationship of presence of progesterone receptors to prognosis in early breast cancer. Cancer Res 40: 3357–3360, 1980
Westerberg H, Gustafson SA, Nordenskjöld B, Silfersward C, Wallgren A: Estrogen receptor level and other factors in early recurrence of breast cancer. Int J Cancer 26: 429–433, 1980
Hawkins RA, Roberts MM, Forrest APM: Oestrogen receptors and breast cancer: Current status. Br J Surg 67: 153–169, 1980
Cheix F, Biron A, Bailly C, Mayer M, Pommatau E, Saez S: Cancer du sein operable: valeur pronostique du nombre des recepteurs d'estradiol. Nouv Press Med 9: 933–935, 1980
Blamey RW, Bishop HM, Blake JRS, Doyle PJ, Elston CW, Haybittle JL, Nicholson RI, Griffiths K: Relationship between primary breast cancer tumor receptor status and patients survival. Cancer 46: 2765–2769, 1980
Rainer H, Bettelheim P, Bieglmayer Ch, Chaput B, Jakesz R, Kees A, Kolb R, Mörz R, Moser K, Reiner G, Schemper M, Spona J: Prognostische Bedeutung von Östrogenrezeptoren beim Mammakarzinom. Wien Klin Woch 92: 796–800, 1980
Gapinsky PV, Donegan WL: Estrogen receptors and breast cancer: prognostic and therapeutic implications. Surgery 88: 386–393, 1980
Hartveit F, Maartmann-Moe H, Støa KF, Tangen M, Thorsen T: Early recurrence in estrogen receptor negative breast carcinomas. Acta Chir Scand 146: 93–95, 1980
Valagussa P, DiFronzo G, Bignami P, Buzzoni R, Bonadonna G, Veronesi U: Prognostic importance of estrogen receptors to select node negative patients for adjuvant chemotherapy. In: Salmon SE, Jones SE (eds): Adjuvant Therapy of Cancer III. Grune and Stratton, New York, 1981, pp 329–333
Bertuzzi A, Vezzoni P, Ronchi E: Prognostic importance of progesterone receptors (PR) alone or in combination with estrogen receptors (ER) in node negative (N-) breast carcinoma (Abstract). In: Proceedings of the American Society of Clinical Oncology. Waverly Press, Baltimore, 1981, p 447
Samaan NA, Buzdar AK, Aldinger KA, Schultz PN, Yang KP, Romsdahl MM, Martin R: Estrogen receptor: a prognostic factor in breast cancer. Cancer 47: 554–560, 1981
Kinne DW, Ashikari R, Butler A, Menendez-Botet C, Rosen PP, Schwartz M: Estrogen receptor protein in breast cancer as a predictor of recurrence. Cancer 47: 2364–2367, 1981
Godolphin W, Elwood JM, Spinelli JJ: Estrogen receptor quantitation and staging as complementary prognostic indicators in breast cancer: a study of 583 patients. Int J Cancer 28: 677–683, 1981
Crowe JP, Hubay CA, Pearson OH, Marshall JS, Rosenblatt J, Mansour EG, Hermann RE, Jones JC, Flynn WJ, McGuire WL and Participating Investigators: Estrogen receptor status as a prognostic indicator for stage I breast cancer patients. Breast Cancer Res Treat 2: 171–176, 1982
Raemaekers JMM, Beex LVAM, Koenders AJM, Smals AGH, Pieters GFFM, Benraad ThJ, Kloppenborg PWC and the Werkgroep Mammacarcinoom: De prognostische betekenis van onderzoek naar receptoractiviteit voor oestradiol in het tumorweefsel van patienten met een primair mammacarcinoom. Ned Tijdschr Geneeskd 126: 1493–1498, 1982
Neifeld JP, Lawrence W Jr, Brown PW, Banks WL, Ierz JJ: Estrogen receptors in primary breast cancer. Arch Surg 117: 753–757, 1982
Paterson AHG, Zuck VP, Szafran O, Lees AW, Hanson J: Influence and significance of certain prognostic factors on survival in breast cancer. Eur J Cancer Clin Oncol 18: 937–943, 1982
Logan LA, Cripps MC, Hirte WE, Rapp EF: The estrogen receptor test: a prognostic tool in primary breast cancer. Can J Surg 25: 581–584, 1982
Pascual MR, Macias A, Moreno L, Lage A: Factors associated with prognosis in human breast cancer: III. Estradiol receptors and short-term relapse. Neoplasma 30: 589–592, 1983
Clark GM, McGuire WL, Hubay CA, Pearson OH, Marshall JS: Progesterone receptors as a prognostic factor in stage II breast cancer. New Eng J Med 309: 1343–1347, 1983
Hähnel R, Woodings T, Vivian AB: Prognostic value of estrogen receptors in primary breast cancer. Cancer 44: 671–675, 1979
Furmanski P, Saunders DE, Brooks SC, Rich MA and the Breast Cancer Prognostic Study Clinical and Pathology Associates: The prognostic value of estrogen receptor determinations in patients with primary breast cancer: an update. Cancer 46: 2794–2796, 1980
van Maillot K, Horke W, Prestele H: Prognostic significance of the steroid receptor content in primary breast cancer. Arch Gynaecol 231: 185–190, 1982
Howat JMT, Barnes DM, Harris M, Swindell R: The association of cytosol oestrogen and progesterone receptors with histological features of breast cancer and early recurrence of disease. Br J Cancer 47: 629–640, 1983
Saez S, Cheix F, Asselain B: Prognostic value of estrogen and progesterone receptors in primary breast cancer. Breast Cancer Res Treat 3: 345–354, 1983
Union Internationale contre le Cancer: TNM classification of malignant tumors. UICC, Geneve, 1978
Koenders AJ, Geurts-Moespot J, Kho KH, Benraad ThJ: Estradiol and progesterone receptor activities in stored lyophilized target tissue. J Steroid Biochem 9: 947–950, 1978
Kaplan EL, Meier P: Non parametric estimation from incomplete observations. J Am Statist Assoc 53: 457–481, 1958
Gehan E: A generalized Wilcoxon test for comparing arbitrarily single censored samples. Biometrika 52: 203–224, 1965
Mantel N: Ranking procedures for arbitrarily restricted observations. Biometrics 23: 65–78, 1967
Hilf R, Feldstein ML, Gibson SL, Savlov ED: The relative importance of estrogen receptor analysis as a prognostic factor for recurrence or response to chemotherapy in women with breast cancer. Cancer 45: 1993–2000, 1980
Bloom ND, Degenshein GA: Estrogen receptors and disease free interval: a dissenting opinion. Breast 6: 25–27, 1980
Skinner JR, Wanebo HJ, Betsill WL, Wilhelm MC, Drake ChR, McLeod RM: Evaluation of the pathologic and prognostic correlates of estrogen receptors in primary breast cancer. Ann Surg 196: 636–641, 1982
Kaufmann M, Klinga K: Mögliche prognostische Kriterien zur Therapie-verbesserung beim primären Mammakarzinom. Geburtsh u Frauenheilk 42: 501–509, 1982
Stewart JF, King RJB, Winter PJ, Tong D, Hayward JL, Rubens RD: Oestrogen receptors, clinical features and prognosis in stage III breast cancer. Eur J Cancer Clin Oncol 18: 1315–1320, 1982
Stewart JF, Rubens RD, Millis RR, King RJB, Hayward JL: Steroid receptors and prognosis in operable (stage I and II) breast cancer. Eur J Cancer Clin Oncol 19: 1381–1387, 1983
Ciatto S, Bravetti P, Cardona G, Cataliotti L, Crescioli R, Herd-Smith A, Messeri G: Prognostic role of estrogen receptor determination in breast cancer. Tumori 69: 527–530, 1983
Mason BH, Holdaway IM, Mullins PR, Yee LH, Kay RG: Progesterone and estrogen receptors as prognostic variables in breast cancer. Cancer Res 43: 2985–2990, 1983
Caldarola L, Calderini P, Volterrani P, DiCarlo P, Gaglia P: The correlation between estrogen receptor status, axillary-node metastases and disease free interval after surgery in primary breast cancer. Ital J Surg Sci 13: 179–185, 1983
Howell A, Harland RNL, Bramwell VHC, Swindell R, Barnes DM, Redford J, Wilkinson MJS, Crowther D, Sellwood RA: Steroid-hormone receptors and survival after first relapse in breast cancer. Lancet i: 588–591, 1984
Alanko A, Heinonen E, Scheinin TM, Tolppanen EM, Vihko RV: Oestrogen and progesterone receptors and disease free interval in primary breast cancer. Cancer 50: 667–672, 1984
Aamdal S, Børmer O, Jørgensen O, Høst H, Eliassen G, Kaalhus O, Pihl A: Estrogen receptors and long-term prognosis in breast cancer. Cancer 53: 2525–2529, 1984
Parl FF, Schmidt BP, Dupont WD, Wagner RK: Prognostic significance of estrogen receptor status in breast cancer in relation to tumor stage, axillary-node metastases, and histopathologic grading. Cancer 54: 2237–2242, 1984
Author information
Authors and Affiliations
Consortia
Rights and permissions
About this article
Cite this article
Raemaekers, J.M.M., Beex, L.V.A.M., Koenders, A.J.M. et al. Disease-free interval and estrogen receptor activity in tumor tissue of patients with primary breast cancer: analysis after long-term follow-up. Breast Cancer Res Tr 6, 123–130 (1985). https://doi.org/10.1007/BF02235743
Issue Date:
DOI: https://doi.org/10.1007/BF02235743